1. Home
  2. LRMR vs NAN Comparison

LRMR vs NAN Comparison

Compare LRMR & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRMR
  • NAN
  • Stock Information
  • Founded
  • LRMR N/A
  • NAN 1999
  • Country
  • LRMR United States
  • NAN United States
  • Employees
  • LRMR N/A
  • NAN N/A
  • Industry
  • LRMR Biotechnology: Pharmaceutical Preparations
  • NAN Investment Managers
  • Sector
  • LRMR Health Care
  • NAN Finance
  • Exchange
  • LRMR Nasdaq
  • NAN Nasdaq
  • Market Cap
  • LRMR 309.8M
  • NAN 337.8M
  • IPO Year
  • LRMR N/A
  • NAN N/A
  • Fundamental
  • Price
  • LRMR $4.13
  • NAN $11.43
  • Analyst Decision
  • LRMR Strong Buy
  • NAN
  • Analyst Count
  • LRMR 7
  • NAN 0
  • Target Price
  • LRMR $16.71
  • NAN N/A
  • AVG Volume (30 Days)
  • LRMR 5.0M
  • NAN 74.6K
  • Earning Date
  • LRMR 11-14-2025
  • NAN 01-01-0001
  • Dividend Yield
  • LRMR N/A
  • NAN 4.37%
  • EPS Growth
  • LRMR N/A
  • NAN N/A
  • EPS
  • LRMR N/A
  • NAN N/A
  • Revenue
  • LRMR N/A
  • NAN N/A
  • Revenue This Year
  • LRMR N/A
  • NAN N/A
  • Revenue Next Year
  • LRMR N/A
  • NAN N/A
  • P/E Ratio
  • LRMR N/A
  • NAN N/A
  • Revenue Growth
  • LRMR N/A
  • NAN N/A
  • 52 Week Low
  • LRMR $1.61
  • NAN $9.11
  • 52 Week High
  • LRMR $9.50
  • NAN $11.34
  • Technical
  • Relative Strength Index (RSI)
  • LRMR 47.65
  • NAN 51.43
  • Support Level
  • LRMR $3.88
  • NAN $11.41
  • Resistance Level
  • LRMR $4.53
  • NAN $11.48
  • Average True Range (ATR)
  • LRMR 0.42
  • NAN 0.09
  • MACD
  • LRMR -0.06
  • NAN -0.01
  • Stochastic Oscillator
  • LRMR 51.10
  • NAN 39.47

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

About NAN Nuveen New York Quality Municipal Income Fund

Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: